S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023

Amarin Stock Price, News & Analysis (NASDAQ:AMRN)

$0.75
+0.01 (+1.35%)
(As of 11/29/2023 ET)
Compare
Today's Range
$0.73
$0.76
50-Day Range
$0.66
$0.95
52-Week Range
$0.65
$2.23
Volume
919,825 shs
Average Volume
1.26 million shs
Market Capitalization
$302.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.08

Amarin MarketRank™ Stock Analysis

Analyst Rating
Sell
1.33 Rating Score
Upside/​Downside
44.4% Upside
$1.08 Price Target
Short Interest
Healthy
3.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.18) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

777th out of 949 stocks

Pharmaceutical Preparations Industry

368th out of 432 stocks


AMRN stock logo

About Amarin Stock (NASDAQ:AMRN)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

AMRN Stock Price History

AMRN Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript
Amarin Reports Third Quarter 2023 Financial Results
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Amarin: Q3 Earnings Snapshot
Amarin Corp PLC ADR AMRN
Amarin Reports Second Quarter 2023 Financial Results
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
365
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$1.08
High Stock Price Target
$1.25
Low Stock Price Target
$1.00
Potential Upside/Downside
+44.4%
Consensus Rating
Sell
Rating Score (0-4)
1.33
Research Coverage
3 Analysts

Profitability

Net Income
$-105,800,000.00
Pretax Margin
-17.99%

Debt

Sales & Book Value

Annual Sales
$369.19 million
Book Value
$1.37 per share

Miscellaneous

Free Float
368,252,000
Market Cap
$302.87 million
Optionable
Optionable
Beta
2.11

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Thomas Charles Reilly (Age 51)
    Chief Financial Officer
    Comp: $856.49k
  • Dr. Steven B. Ketchum Ph.D. (Age 58)
    President of Research & Development and Chief Scientific Officer
    Comp: $991.19k
  • Mr. Aaron D. Berg (Age 60)
    Executive VP & President of U.S.
    Comp: $913.7k
  • Mr. Patrick Holt
    President, CEO & Director
  • Mr. Jordan Zwick (Age 36)
    Senior VP of Corporate Business Development & Investor Relations
  • Ms. Donna Pasek
    Senior Vice President of Human Resources
  • Mr. Laurent Abuaf
    President of Europe & Senior VP
  • Dr. Nabil Abadir
    Chief Medical Officer of Global Medical Affairs
  • Dr. David Keenan Ph.D.
    Executive VP of Technical Operations & President of Europe














AMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" AMRN shares.
View AMRN analyst ratings
or view top-rated stocks.

What is Amarin's stock price target for 2024?

3 analysts have issued 1-year price objectives for Amarin's shares. Their AMRN share price targets range from $1.00 to $1.25. On average, they predict the company's stock price to reach $1.08 in the next year. This suggests a possible upside of 44.4% from the stock's current price.
View analysts price targets for AMRN
or view top-rated stocks among Wall Street analysts.

How have AMRN shares performed in 2023?

Amarin's stock was trading at $1.21 at the beginning of 2023. Since then, AMRN shares have decreased by 38.0% and is now trading at $0.75.
View the best growth stocks for 2023 here
.

When is Amarin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our AMRN earnings forecast
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The biopharmaceutical company earned $66.06 million during the quarter, compared to analysts' expectations of $57.56 million. Amarin had a negative net margin of 16.27% and a negative trailing twelve-month return on equity of 9.12%.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Who are Amarin's major shareholders?

Amarin's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kynam Capital Management LP (2.98%), SCP Investment LP (0.74%), Stadium Capital Management LLC (0.47%), 13D Management LLC (0.37%), Axxcess Wealth Management LLC (0.32%) and UBS Group AG (0.19%). Insiders that own company stock include David M Stack, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Amarin have any subsidiaries?
The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More
This page (NASDAQ:AMRN) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -